NASDAQ:ANEB

Anebulo Pharmaceuticals (ANEB) Stock Forecast, Price & News

$2.38

+0.02 (+0.85%)

(As of 05/26/2023 08:46 PM ET)

Compare

Today's Range: $2.38
▼
$2.38
50-Day Range: $2.06
▼
$2.98
52-Week Range: $1.77
▼
$7.00

Volume: 700 shs
Average Volume: 5,120 shs
Market Capitalization: $61.00 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Anebulo Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 194.1% Upside
$7.00 Price Target
Short Interest: Healthy
0.09% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.48) to ($0.53) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

409th out of 1,010 stocks

Pharmaceutical Preparations Industry

188th out of 494 stocks

3.5

Analyst's Opinion

Consensus Rating
Anebulo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, Anebulo Pharmaceuticals has a forecasted upside of 194.1% from its current price of $2.38.
Amount of Analyst Coverage
Anebulo Pharmaceuticals has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.09% of the float of Anebulo Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Anebulo Pharmaceuticals has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Anebulo Pharmaceuticals has recently decreased by 18.64%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Anebulo Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Anebulo Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ANEB.

2.7

News and Social Media Coverage

News Sentiment
Anebulo Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Anebulo Pharmaceuticals this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Anebulo Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
85.70% of the stock of Anebulo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 26.70% of the stock of Anebulo Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Anebulo Pharmaceuticals are expected to decrease in the coming year, from ($0.48) to ($0.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Anebulo Pharmaceuticals is -5.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Anebulo Pharmaceuticals is -5.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Anebulo Pharmaceuticals has a P/B Ratio of 4.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.

Receive ANEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANEB Stock News Headlines

May 19, 2023 | finance.yahoo.com

Down -26.43% in 4 Weeks, Here's Why You Should You Buy the Dip in Anebulo Pharmaceuticals, Inc. (ANEB)

May 18, 2023 | msn.com

Benchmark Reiterates Anebulo Pharmaceuticals (ANEB) Speculative Buy Recommendation

May 29, 2023 | Stocks To Trade (Ad)

15 A.I. Trading Opportunities a Day

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

May 16, 2023 | americanbankingnews.com

Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Decreases By 9.2%

May 11, 2023 | finanznachrichten.de

Anebulo Pharmaceuticals, Inc.: Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

May 11, 2023 | msn.com

Anebulo Pharmaceuticals: Q3 Earnings Insights

May 11, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

May 1, 2023 | americanbankingnews.com

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update

May 29, 2023 | Stocks To Trade (Ad)

15 A.I. Trading Opportunities a Day

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

April 16, 2023 | americanbankingnews.com

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 460.0% in March

March 29, 2023 | msn.com

Antidote For THC? Anebulo Releases Positive Clinical Data Showing Potential Of Its Drug For Treatment Of Acute Cannabinoid Intoxication

March 28, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

March 8, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

February 19, 2023 | barrons.com

Anebulo Pharmaceuticals Inc.

February 10, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

January 27, 2023 | seekingalpha.com

Anebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains Unclear

January 9, 2023 | msn.com

Acute Cannabinoid Intoxication: This Pharma Company's Clinical Trials To Reduce And Treat Symptoms

January 9, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

December 21, 2022 | finance.yahoo.com

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

November 10, 2022 | finance.yahoo.com

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates

November 1, 2022 | finance.yahoo.com

Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

September 26, 2022 | finance.yahoo.com

Lower Doses Of Anebulo's ANEB-001 Reduces Negative Effects Of Higher Doses Of THC

September 26, 2022 | finance.yahoo.com

Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing

September 26, 2022 | finance.yahoo.com

Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

September 20, 2022 | finance.yahoo.com

Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022

September 10, 2022 | investing.com

Anebulo Pharmaceuticals Earnings Miss, Revenue Inline In Q1

September 10, 2022 | seekingalpha.com

Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ANEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANEB Company Calendar

Last Earnings: 11/12/2021
Today: 5/28/2023
Fiscal Year End: 6/30/2023
Next Earnings (Estimated): 9/08/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ANEB
CUSIP: N/A
CIK: 1815974
Web: www.anebulo.com
Phone: 512-598-0931
Fax: N/A
Employees: 2
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.00
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +194.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,830,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -73.82%
Return on Assets: -69.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.68
Quick Ratio: 9.68

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.50 per share
Price / Book: 4.76

Miscellaneous

Outstanding Shares: 25,630,000
Free Float: 3,666,000
Market Cap: $61.00 million
Optionable: Not Optionable
Beta: -1.42

Key Executives

Dr. Joseph F. Lawler M.D. (Age 50)
Ph.D., Founder & Chairman
Comp: $11k

Mr. Simon J. Allen B.Sc. (Age 54)
M.B.A., MBA, CEO & Director
Comp: $450k

Mr. Rex Merchant CFA (Age 62)
CFO & Sec.
Comp: $275k

Dr. Kenneth C. Cundy Ph.D. (Age 63)
Chief Scientific Officer
Comp: $345.53k

Mr. Scott L. Anderson
Head of Investor Relations & Public Affairs

Key Competitors

View All Competitors

ANEB Stock - Frequently Asked Questions

Should I buy or sell Anebulo Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANEB shares.
View ANEB analyst ratings or view top-rated stocks.
What is Anebulo Pharmaceuticals' stock price forecast for 2023?: 2 Wall Street analysts have issued 1-year price objectives for Anebulo Pharmaceuticals' shares. Their ANEB share price forecasts range from $6.00 to $8.00. On average, they predict the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 194.1% from the stock's current price.
View analysts price targets for ANEB or view top-rated stocks among Wall Street analysts.
How have ANEB shares performed in 2023?: Anebulo Pharmaceuticals' stock was trading at $2.4237 at the beginning of the year. Since then, ANEB stock has decreased by 1.8% and is now trading at $2.38.
View the best growth stocks for 2023 here.
When is Anebulo Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, September 8th 2023.
View our ANEB earnings forecast.
How were Anebulo Pharmaceuticals' earnings last quarter?: Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.04.

When did Anebulo Pharmaceuticals IPO?: (ANEB) raised $21 million in an IPO on Friday, May 7th 2021. The company issued 3,000,000 shares at a price of $6.00-$8.00 per share. The Benchmark Company served as the underwriter for the IPO.
What is Anebulo Pharmaceuticals' stock symbol?: Anebulo Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANEB."
How do I buy shares of Anebulo Pharmaceuticals?: Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Anebulo Pharmaceuticals' stock price today?: One share of ANEB stock can currently be purchased for approximately $2.38.
How much money does Anebulo Pharmaceuticals make?: Anebulo Pharmaceuticals (NASDAQ:ANEB) has a market capitalization of $61.00 million. The company earns $-6,830,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.
How can I contact Anebulo Pharmaceuticals?: The official website for the company is www.anebulo.com. The company can be reached via phone at 512-598-0931 or via email at ybriggs@lhai.com.

This page (NASDAQ:ANEB) was last updated on 5/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Anebulo Pharmaceuticals (ANEB) Stock Forecast, Price & News

Anebulo Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock

ANEB Stock News Headlines

ANEB Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ANEB Stock - Frequently Asked Questions

Overall MarketRank^™